Professor Soria talks to ecancer about mutant specific kinases including data from the TIGERX phase I/II study with rociletinib, an irreversible epidermal growth factor receptor (EGFR)-mutant selective inhibitor.

As the outgoing president of the meeting, Professor Soria also provides a general overview of TAT 2015 and provides some scientific and personal highlights. He also encourages participation in TAT 2016 which will be held next year in Washington DC, USA.